CACLP - The largest IVD Expo & Conference

CSRC Approved IPO Registration Applied by Sino Biological

Industry news | 16 July, 2021 | CACLP



On July 14, China Securities Regulatory Commission (CSRC) released the news and approved the IPO registration of Sino Biological, Inc. Sino Biological is an international reagent supplier and service provider, which specializes in recombinant protein production and antibody development. All of Sino Biological's products are independently developed and produced, including recombinant proteins, antibodies and cDNA clones. Sino Biological is the researchers' one-stop technical services shop for the advanced technology platforms they need to make advancements. In addition, Sino Biological offers pharmaceutical companies and biotechnology firms pre-clinical production technology services for hundreds of monoclonal antibody drug candidates. The company possesses 330+ research staff with 33.34% master or Ph. D degree. There is 66,000 sq ft Lab & Office Space and 25,000 sq ft GMP Facility.



Sino Biological is committed to providing high-quality recombinant protein and antibody reagents and to being a one-stop technical services shop for life science researchers around the world. All of the products are independently developed and produced. In addition, the company offers pharmaceutical companies and biotechnology firms pre-clinical production technology services for hundreds of monoclonal antibody drug candidates. The product quality control indicators meet rigorous requirements for clinical use samples. It takes only a few weeks to produce 1 to 30 grams of purified monoclonal antibody from gene sequencing.


Innovation permeates all aspects of Sino Biological's enterprise, making it one of the largest mainstream suppliers of protein and antibody research tools in the world. Sino Biological has a suite of advanced core technologies. The company's established technology platforms have full-level carrying capacity, with the ability to move research and development from the pilot test phase to full-scale production. The platforms can realize high-throughput and high-efficiency research and production of recombinant protein or antibody reagents. Sino Biological follows stringent standards and quality control systems in developing and producing biological reagents.


Based on its own core technology, the company has produced and sold more than 47,000 kinds of spot products, including more than 6,000 kinds of recombinant protein reagents and 13,000 kinds of antibody reagents. In addition, there are more than 10,000 kinds of antibodies, nearly 30,000 kinds of genes and other high-quality reagent products, which can cover many fields of life science research.


Filed under:
Press contact CACLP - The largest IVD Expo & Conference

Stay in touch with CACLP News

We deliver the latest IVD news straight to your inbox. Stay in touch with CACLP News, sign-up for our newsletter today.

  • Name *
  • Email *
  • Company name *
  • Country *
    CACLP - The largest IVD Expo & Conference

By subscribing our newsletter, you agree to our Privacy Policy. You can unsubscribe at anytime.

Share
Opening Countdown
0 0 0

Day(s)

0 0

Hour(s)

0 0

Min(s)

Room 2201-2203 & 2205, Cloud Nine Plaza
1118 West Yan’an Road
Shanghai, China
200052

Copyright © 2024 GL events Ruihe (Shanghai) Exhibition Co., Ltd. All Rights Reserved. ( 沪ICP备12004745号-1 )

We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy & Cookies for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

CACLP - The largest IVD Expo & Conference